Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

Item

http://www.wikidata.org/entity/Q39020800

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

@en

Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

@nl

type

Item

label

Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

@en

Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

@nl

prefLabel

Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

@en

Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

@nl

P1476

Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

@en

P2093

Chia-Ching J Wang

http://www.w3.org/2001/XMLSchema#string

Joel M Palefsky

http://www.w3.org/2001/XMLSchema#string

P2860

Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia

Case-control study of human papillomavirus and oropharyngeal cancer

Cancer statistics, 2016

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

P304

17-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SOC.2016.07.010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joseph A Sparano

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27889034

http://www.w3.org/2001/XMLSchema#string

P932

5331942

http://www.w3.org/2001/XMLSchema#string